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178Objective: Cardiopulmonary bypass is associated with ischemia–reperfusion injury to multiple organs. We
aimed to evaluate whether remote ischemic preconditioning performed the day before surgery for congenital
heart disease with cardiopulmonary bypass attenuates the postoperative inflammatory response and myocardial
dysfunction.
Methods: This was a prospective, randomized, single-blind, controlled trial. Children allocated to remote ische-
mic preconditioning underwent 4 periods of 5 minutes of lower limb ischemia by a blood pressure cuff interca-
lated with 5 minutes of reperfusion. Blood samples were collected 4, 12, 24, and 48 hours after cardiopulmonary
bypass to evaluate nuclear factor kappaB activation in leukocytes by quantification of mRNA of I kappaB alpha
by real-time quantitative polymerase chain reaction and for interleukin-8 and 10 plasma concentration measure-
ments by enzyme-linked immunosorbent assay. Myocardial dysfunction was assessed by N-terminal pro-B-type
natriuretic peptide and cardiac troponin I plasma concentrations, measured by chemiluminescence, and clinical
parameters of low cardiac output syndrome.
Results: Twelve children were allocated to remote ischemic preconditioning, and 10 children were allocated to
the control group. Demographic data and Risk Adjustment for Congenital Heart Surgery 1 classification were
comparable in both groups. Remote ischemic preconditioning group had lower postoperative values of
N-terminal pro-B-type natriuretic peptide, but cardiac troponin I levels were not significantly different between
groups. Interleukin-8 and 10 concentrations and I kappa B alpha gene expression were similar in both groups.
Postoperative morbidity was similar in both groups; there were no postoperative deaths in either group.
Conclusions: Late remote ischemic preconditioning did not provide clinically relevant cardioprotection to chil-
dren undergoing cardiopulmonary bypass. (J Thorac Cardiovasc Surg 2012;144:178-83)Supplemental material is available online.
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The Journal of Thoracic and Cardiovascular SurgIschemic preconditioning is a phenomenon of organ pro-
tection promoted by brief periods of nonlethal ischemia that
protect against subsequent lethal ischemia. Remote ische-
mic preconditioning (RIPC) is a technique in which tran-
sient ischemia in one tissue or organ confers subsequent
protection to distant organs subjected to potentially lethal
ischemia. The first phase of protection, called ‘‘early ische-
mic preconditioning,’’ manifests immediately after the
stimulus and lasts for 1 to 2 hours. The second phase, called
the ‘‘second window of protection’’ or ‘‘late ischemic pre-
conditioning,’’ appears 24 to 48 hours later and lasts for
48 to 72 hours.2
The mechanism of protection induced by RIPC involves
the release of one or more substances into the systemic
circulation that have multiorgan protective effects.3,4
Cardioprotection induced by late ischemic preconditioning
involves upregulation of anti-inflammatory gene expression,
suppression of proinflammatory genes, and reduction of neu-
trophil adhesion.3,5 To date, there are no published studies on
the effects of late ischemic preconditioning performed alone
in pediatric patients undergoing cardiac surgery with CPB.
Thus, we aimed to investigate whether RIPC performed 24
hours before cardiac surgery with CPB would reduce the
inflammatory response and myocardial dysfunction in
children with congenital heart disease.ery c July 2012
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
cTnI ¼ cardiac troponin I
IkBa ¼ I kappa B alpha
IL ¼ interleukin
NF-kB ¼ nuclear factor kappa B
NT-
proBNP
¼ N-terminal pro-B-type natriuretic
peptide
PELOD ¼ Pediatric Logistic Organ Dysfunction
PICU ¼ pediatric intensive care unit
RACHS ¼ Risk Adjustment for Congenital Heart
Surgery
RIPC ¼ remote ischemic preconditioning
TnI ¼ troponin I
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This is a prospective, randomized, single-blind, controlled trial. The
study was approved by the Institutional and National Research Ethics
Boards and registered at the international registry of clinical trials in hu-
mans (www.clinicaltrial.gov) under the number NCT00868101. Written
informed consent was obtained from the patients’ parents. Children aged
1 month to 2 years admitted to the Pediatric Cardiology ward in the preop-
erative period and to the pediatric intensive care unit (PICU) in the postop-
erative period were eligible for the study. The noninclusion criteria were
the presence of genetic syndromes, uncontrolled infection preoperatively,
immunodeficiency, class I of Risk Adjustment for Congenital Heart
Surgery (RACHS) 1 score,6 and nonapproval by parents. The exclusion
criteria were incomplete application of the preconditioning protocol and
parents’ request.
After informed consent was obtained, patients were randomized to the
experimental or control group by means of a list generated by a computer-
ized system that uses a random number generator to produce customized
sets of random numbers (www.randomizer.org). Patients allocated to the
RIPC group underwent 4 periods of 5 minutes of lower limb ischemia in-
tercalated with 5 minutes of reperfusion on the cardiology ward approxi-
mately 24 hours before cardiac surgery. By using an electronic
sphygmomanometer (Dixtal model 2710; Dixtal Biomedica, S~ao Paulo,
Brazil) with an appropriately sized cuff, the patients had their blood pres-
sure measured twice in the legs with a 2-minute interval between measure-
ments. A 123 6-cm sphygmomanometer cuff (Becton Dickinson, Franklin
Lakes, NJ) was then inflated in the same leg to a pressure 15 mm Hg above
the average of the previously measured values of the systolic pressure, and
the limb was maintained ischemic with the cuff inflated for 4 periods of 5
minutes, which were intercalated with periods of 5 minutes of reperfusion.
All parents were invited to stay with their child during preconditioning.
Minimal sedation with oral chloral hydrate (40 mg/kg) or intravenous mid-
azolam (0.1–0.2 mg/kg) was used in cases of extreme patient anxiety re-
lated to the procedure.
All patients were operated on by the same cardiac surgery team. CPB
was performed using a BM-6 device (Edwards Lifesciences, Irvine, Calif)
with alpha-stat at 28C, colloid priming, cold blood cardioplegia, and mod-
ified ultrafiltration. A bolus dose of 30 mg/kg of methylprednisolone was
administered to all patients at CPB start. Inhalational anesthesia (sevoflur-
ane or isoflurane) and intravenous fentanyl were administered to all pa-
tients. Postoperative care was delivered in the PICU by trained staff
according to standard protocols.7 The teams responsible for intraoperative
and postoperative care were blind to the group to which the patient
belonged.The Journal of Thoracic and CaBlood samples (2.5 mL into EDTA vacuum tubes) were obtained from
arterial or central venous lines, inserted before surgery, at 4, 12, 24, and 48
hours after CPB end for evaluation of the inflammatory response and bio-
markers of myocardial dysfunction. Inflammatory response was assessed
by nuclear factor kappaB (NF-kB) activation in leukocytes and interleukin
(IL)-8 and IL-10 plasma concentrations. Because there is evidence showing
an inverse correlation between natriuretic peptide type B levels and left
ventricular ejection fraction in various clinical scenarios, including con-
genital heart disease,8 and an association between increased plasma levels
of natriuretic peptide type B and its inactive form N-terminal pro-B-type
natriuretic peptide (NT-proBNP), as well as cardiac troponin I (cTnI)
with low cardiac output syndrome in children undergoing CPB,9-12
NT-proBNP and cTnI were chosen as the biomarkers of myocardial dys-
function for this study.
Samples were immediately centrifuged at 10C, 3000 rpm, and plasma
was separated and stored at70C until analysis. The pellet containing
blood cells was lysed with ammonium bicarbonate plus ammonium chlo-
ride solution and centrifuged at 3000 rpm for 15 minutes at 4C. The super-
natant was discarded, and the remaining pellet containing RNA, DNA, and
protein was resuspended in phosphate-buffered solution and Trizol LS (In-
vitrogen Corporation, Carlsbad, Calif), and stored at70C.
RNA was extracted using the chloroform/isopropanol/ethanol method
and quantified by spectrophotometry at 260 nm (Eppendorf BioPhotometer
Plus, Eppendorf AG, Hamburg, Germany). Its quality was assessed in
1.2% agarose gel electrophoresis. Complementary DNA was synthesized
with a commercially available kit (High Capacity cDNA Reverse Tran-
scription Kit; Applied Biosystems, Foster City, Calif), according to the
manufacturer’s instructions. NF-kB activity in peripheral blood mononu-
clear cells and neutrophils was assessed by the relative gene expression
of its inhibitor, I kappa B alpha (IkBa) by real-time quantitative polymer-
ase chain reaction (7500 Real Time PCR System, Applied Biosystems),13
using a TaqMan probe for human IkBa (reference: Hs_00153283_m1, Re-
porter: FAM) (Applied Biosystems) and b-actin (Reporter: FAM) (Applied
Biosystems) as endogenous control. All tests were performed in duplicate.
IkBa relative gene expression was calculated by the 2-DDCT method, as pre-
viously described.14 The calibrator was RNA from 12 healthy children. To
validate the use of relative IkBa gene expression as an indicator of NF-kB
activation, we performed the relative quantification of total NF-kB in the
pool of proteins extracted from lysates of peripheral blood mononuclear
cells by Western blot, using b-actin as endogenous control.
IL-8 and 10 plasma concentrations were measured by enzyme-linked
immunosorbent assay (BD OptEIA, BD Biosciences Pharmingen, San
Diego, Calif). Plasma concentrations of cTnI were quantified by solid-
phase chemiluminescence immunoassay using the Immulite 1000 analyzer
(Siemens Medical Solutions Diagnostics, Los Angeles, Calif). NT-proBNP
plasma concentrations were measured by enzyme electrochemilumines-
cence immunoassay using the Cobas E 411 analyzer (Roche Diagnostics,
Basel, Switzerland).
Demographic and clinical data were collected from patients’ health re-
cords. An adapted inotropic score was calculated as follows: doses of
dopamine þ dobutamine þ milrinone 3 10 þ epinephrine 3 100 þ
norepinephrine3 100.15Organ dysfunctionwas assessed byPediatricLogis-
ticOrganDysfunction (PELOD) score.16Procedure complexitywas stratified
according to RACHS-1 score,5 and severity of illness was assessed by Pedi-
atric Risk ofMortality score between 8 and 24 hours after PICU admission.17
The primary outcome measurewas the concentration of IL-8 4 hours after
surgery. Secondary end points included NF-kB activation in leukocytes; post-
operative concentrations of IL-10,NT-proBNP, and cTnI; duration ofmechan-
ical ventilation; incidence of arrhythmia; PELODscore at 24 hours and on day
2; length of PICU and hospital stay; and mortality up to hospital discharge.Statistical Analysis
Statistical analyses of data were performed using SPSS 16.0 for Win-
dows (SPSS Inc, Chicago, Ill). The primary end point for which our samplerdiovascular Surgery c Volume 144, Number 1 179
Congenital Heart Disease Pavione et al
C
H
Dsize was calculated was the concentration of IL-8 4 hours after surgery, be-
cause it was a good predictor of postoperative low cardiac output syndrome
and a good marker of inflammation in a previous study of our group.12 In
this study, we found that the difference between the means of IL-8 concen-
trations 4 hours after surgery among patients who developed low cardiac
output syndrome postoperatively and those who did not develop low car-
diac output syndromewas 190 pg/mL (standard deviation, 155). To normal-
ize data, logarithmic transformation was performed, and we found that the
difference between means of IL-8 concentrations 4 hours after surgery was
0.8 (standard deviation, 0.6). Thus, with a power of 80% and type 1 error
(a) of 5%, and experimental to control ratio of 1:1, we calculated a sample
size of 20 subjects. The analysis was per protocol. Data were expressed as
median (range) or n (%). Comparisons between groups were made using
the Mann–Whitney U test for continuous variables and Fisher exact test
for categoric variables. Variables with repeated measurements were ana-
lyzed using a linear mixed-effects model where time was included as a ran-
dom factor and group membership as a fixed factor. Residuals were tested
for normal distribution, with mean of 0 and variance of s2.
RESULTS
From February 2008 to February 2009, 27 children ad-
mitted to the Pediatric Cardiology ward of Hospital das
Clınicas of Faculty of Medicine of Ribeir~ao Preto of Uni-
versity of S~ao Paulo in the preoperative period were as-
sessed for eligibility, of whom 23 were randomized. Four
patients were excluded for the following reasons: age
more than 2 years (2) and no consent by parents (2). Study
participants were randomly assigned to the RIPC group
(n ¼ 12) and the control group (n ¼ 11). One patient allo-
cated to the control group was excluded because of intrao-
perative death; 22 patients were analyzed (12 in the RIPC
group and 10 in the control group). The flow diagram of
the study is given in Figure E1.
Patients’ age ranged from 1.4 to 21.1 months (median,
5.9 months); 59% were male. RACHS-1 category frequen-
cies in the study population were as follows: category II,
50%; category III, 31.8%; category IV, 18.2% (Table 1).
Baseline demographic and clinical characteristics were
similar in both groups, which shows that the groups were
homogeneous and patients were adequately randomized
(Table 2).
In the experimental group, RIPC was performed 19.1 to
27.5 hours (median, 22.1 hours) before CPB start. In all
cases, the child’s parent or legal guardian was present dur-
ing the procedure, and in the majority of cases, RIPC was
applied with the child on the caregiver’s lap. Most children
tolerated the procedure well, provided they were distracted.
Only 2 children needed sedation with chloral hydrate 40
mg/kg, and 1 of them received also an intravenous bolus
of midazolam 0.1 mg/kg; they were monitored and had no
complications related to sedation. No lower limb complica-
tions that could be attributed to the technique, such as swell-
ing, petechiae, ecchymosis, or thrombosis, were observed
before or after surgery.
Hemodynamic variables (heart rate, systolic blood pres-
sure, and central venous pressure) were similar in both
groups at all time points. Heart rate was significantly higher180 The Journal of Thoracic and Cardiovascular Surgin the experimental group 48 hours after CPB end
(P ¼ .007), but systolic blood pressure and central venous
pressure did not change significantly over time in either
group. There was no difference in the inotropic score be-
tween groups at any time point, but it decreased signifi-
cantly from 24 hours after cessation of CPB in the control
group (P ¼ .0003). Lactate plasma levels were similar in
both groups at all times, and they showed a significant de-
crease equally in both groups from 12 hours after CPB
end (P<.0001). There was no difference between groups
in urine output and creatinine concentrations, and values
did not change significantly over time in either group.
There was no significant difference in cTnI concentra-
tions between groups at any sampling time, and they de-
creased significantly over time similarly in both groups
(P<.0001) (Figure 1). NT-proBNP levels peaked in both
groups 12 hours after CPB end. The RIPC group, compared
with the control group, had lower NT-proBNP peak concen-
trations (median 8219; range 3684–23,700 vs median
20,697; range 7379–35,000 pg/mL, respectively;
P ¼ .02), lower NT-proBNP concentrations 12 hours
(P ¼ .03) and 24 hours (P ¼ .03) after cessation of CPB,
and lower area under the NT-proBNP curve (P ¼ .02)
(Figure 2).
The distribution of IL-8 and 10 concentrations was sim-
ilar in both groups. They peaked 4 hours after CPB end in
the 2 groups and subsequently decreased equally in both
groups (P<.0001 and P ¼ .001 for IL-8 in experimental
and control groups, respectively; P<.0001 and P ¼ .0003
for IL-10, in experimental and control groups, respectively)
(Figure 3). The quantification of IkBa gene expression also
did not differ between groups at any time point, and values
did not change significantly over time in either group
(P ¼ .58 and P ¼ .32, in experimental and control groups,
respectively) (Figure E2). Relative quantification of total
NF-kB in the pool of proteins extracted from lysates of pe-
ripheral blood mononuclear cells by Western blot using
b-actin as endogenous control was performed in 3 randomly
selected patients. We found that the relative quantification
of IkBa mRNA was inversely related (mirror image) to
the relative quantification of total NF-kB protein
(Figure E3).
No significant difference was observed regarding the du-
ration of mechanical ventilation (median, 1; range, 1–8 vs
median, 1; range, 1–5 days; P ¼ .66), incidence of arrhyth-
mia (4/12 vs 3/10;P¼ 1), PELOD score at 24 hours (median
11; range 1–20 vs median 12; range 1–22; P¼ .16), PELOD
score on day 2 (median, 0; range, 0–10 vs median, 0; range,
0–1; P¼ .3), length of PICU stay (median, 4; range, 2–27 vs
median, 5; range, 2–22 days;P¼ .76), and length of hospital
stay (median, 11; range, 4–43 vs median, 9.5; range, 6–28
days;P¼ .86) between theRIPC and control groups, respec-
tively. There were no postoperative deaths up to hospital
discharge in either group.ery c July 2012
TABLE 1. Demographic and clinical characteristics of all patients
Patient Sex Age (mo) Group Diagnosis
1 M 1.4 RIPC Taussig–Bing anomaly
2 F 1.8 RIPC VSD and PDA
3 M 15.8 RIPC Tricuspid atresia and pulmonary stenosis
4 M 13.7 RIPC Tetralogy of Fallot
5 M 14.3 RIPC Tetralogy of Fallot
6 M 21.1 RIPC Tetralogy of Fallot
7 F 5.0 RIPC Hypoplastic aortic arch, coarctation of the aorta, VSD, and DORV
8 M 1.4 RIPC Total anomalous pulmonary venous connection (supracardiac)
9 F 6.7 RIPC Partial atrioventricular septal defect and pulmonary stenosis
10 F 4.0 RIPC VSD and PDA
11 F 7.9 RIPC Partial atrioventricular septal defect and pulmonary stenosis
12 M 3.0 RIPC VSD and PDA
13 F 13.9 Control Total atrioventricular septal defect
14 F 1.4 Control Hypoplastic aortic arch and coarctation of the aorta
15 F 3.3 Control Hypoplastic aortic arch, coarctation of the aorta, and VSD
16 M 12.4 Control Tetralogy of Fallot
17 M 1.4 Control d-Transposition of the great arteries and VSD
18 M 5.1 Control VSD and PDA
19 M 2.1 Control l-Transposition of the great arteries and DORV
20 F 10.3 Control Mitral atresia and DORV
21 M 8.9 Control Tetralogy of Fallot
22 M 7.2 Control VSD and pulmonary stenosis
VSD, Ventricular septal defect; PA, pulmonary artery; PDA, patent ductus arteriosus; DORV, double-outlet right ventricle.
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This is the first clinical study in children that assessed the
effect of RIPC performed only on the day before cardiac
surgery. Our data showed that children aged less than 2
years with complex congenital heart disease undergoing
RIPC approximately 24 hours before surgery had lower
postoperative levels of NT-proBNP comparedwith a control
group. Nevertheless, clinical parameters of low cardiac out-
put syndrome and the inotropic score, as well as the sys-
temic inflammatory response, were similar in both groups.
In addition, no significant differences were found in clinical
outcomes between the experimental and the control group.
It has been shown that children with various congenital
heart defects undergoing RIPC in the operating roomTABLE 2. Comparisons of demographic and clinical characteristics betwe
Characteristics RIPC group (n ¼ 12)
Gender (male) 7 (58%)
Age at surgery (mo) 5.8 (1.4–21.1)
Weight (kg) 5.3 (2.7–11.4)
Length (cm) 60.5 (49–85)
Body surface area (m2) 0.3 (0.2–0.5)
Preoperative O2 saturation (%) 94 (58–97)
Surgery time (min) 187 (140–300)
Bypass time (min) 92 (55-175)
Aortic crossclamp time (min) 66 (5–120)
PRISM score 6.5 (1–15)
RACHS-1 score (III/ IV) 5 (42%)
Data are expressed as median (range) or n (%). RPIC, Remote ischemic preconditioning;
Surgery.
The Journal of Thoracic and Caimmediately before surgery had lower postoperative levels
of troponin I (TnI), less inotropic requirement, and a more
favorable cytokine profile.18 In addition, children undergo-
ing surgical repair of ventricular septal defects who re-
ceived RIPC 24 hours and 1 hour before surgery start had
reduced TnI release, decreased inotropic need, lower levels
of proinflammatory cytokines, and higher levels of IL-10 in
the postoperative period.19
Studies in adults undergoing elective coronary artery by-
pass graft surgery showed lower troponin T release in those
receiving the RIPC stimulus immediately before sur-
gery.20,21 In addition, a recently published study that
evaluated RIPC performed only on the day before heart
surgery showed that adults submitted to coronary arteryen groups
Control group (n ¼ 10) P value
6 (60%) 1.00
6.1 (1.4–13.9) .64
4.9 (3.0–7.0) .59
61.5 (52–74) .64
0.3 (0.2–0.4) .59
92 (78–97) .84
195 (150–310) .91
90 (35–175) .97
59 (0–113) .42
10.5 (0–19) .11
6 (60%) .26
PRISM, Pediatric Risk of Mortality; RACHS, Risk Adjustment for Congenital Heart
rdiovascular Surgery c Volume 144, Number 1 181
FIGURE 1. Postoperative cTnI plasma levels in patients from RIPC
(hashed boxes) and control (white boxes) groups. Central lines are me-
dians, boxes are interquartile ranges, and brackets are total range. CPB,
Cardiopulmonary bypass; cTnI, cardiac troponin I.
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start had lower levels of TnI 8 hours postoperatively.22
However, morbidity and mortality were not reported in
any of these studies.
In the present study, we observed that levels of cTnI were
not significantly different between groups. On the other
hand, NT-proBNP release was significantly reduced in chil-
dren receiving the preconditioning stimulus, which could in-
dicate less myocardial dysfunction and a cardioprotective
effect elicited by late RIPC. Nonetheless, the significant re-
duction in the biochemical parameter of myocardial dys-
function did not translate into morbidity improvement. In
addition, there was no postoperative mortality in either
group, which is not surprising because death is a rare event
in pediatric cardiac surgery.Moreover, we only studied chil-
dren who were stable in the preoperative period; neonates
and those admitted preoperatively to the PICU, who have
a greater risk of mortality, were not included in this study.
Contrary to our expectations, we did not observe any ben-
eficial effect in the inflammatory response that could beFIGURE 2. Left: Postoperative NT-proBNP plasma levels in patients from RI
dians, boxes are interquartile ranges, and brackets are total range. Right: Areas u
from RIPC (dark gray) and control (light gray) groups. *P ¼ .03. CPB, Cardio
RIPC, remote ischemic preconditioning.
182 The Journal of Thoracic and Cardiovascular Surgattributed to RIPC. Our findings are in contrast with previ-
ously published data showing suppression of proinflamma-
tory gene transcription in human leukocytes after RIPC.5 In
our study, there was no difference in plasma concentrations
of the proinflammatory cytokine IL-8 and the anti-
inflammatory cytokine IL-10 between the RIPC and control
groups. IkBa gene expression, which has been shown to
correlate well with NF-kB activation,13 was also similar
in both groups. The inverse association between the relative
quantification of IkBa mRNA and the relative quantifica-
tion of total NF-kB protein observed in this study is consis-
tent with the fact that when NF-kB binds to DNA, and thus
its relative quantification decreases in the pool of proteins,
the relative amount of IkBa mRNA increases because of
its transcription induced by NF-kB binding to DNA.
Ischemic preconditioning may fail to protect the heart
when the subsequent ischemic insult is too long.23 There-
fore, the long duration of ischemia induced by cardiac sur-
gery may overwhelm the protective effect of RIPC.
However, in our study, CPB and crossclamp times were
not excessively long (90 and 60 minutes, respectively, in
both groups). The question arises whether additional cardi-
oprotection could be observed if early and late RIPC were
applied in combination, as already demonstrated.19 In addi-
tion, the beneficial effect of longer occlusion periods during
preconditioning needs to be explored in further studies.
In the present study, we verified that the protocol of RIPC
using cuff pressures 15 mm Hg above systolic blood pres-
sure was harmless to the children’s limbs. We also added
the information that it is possible to apply the technique
in young infants, without any sedation in most cases.Limitations
This study has some limitations. First, blood samples for
assessment of baseline biochemical markers of myocardial
dysfunction and inflammatory response were not collected
because we assumed that they would be in the normal range
for age, because all patients were stable in the preoperative
period. Second, steroid administration at CPB start andPC (hashed boxes) and control (white boxes) groups. Central lines are me-
nder the curve of postoperative plasma NT-proBNPmean values in patients
pulmonary bypass; NT-proBNP, N-terminal pro-B-type natriuretic peptide;
ery c July 2012
FIGURE 3. Postoperative IL-8 (left) and IL-10 (right) plasma levels in patients from RIPC (hashed boxes) and control (white boxes) groups. Central lines
are medians, boxes are interquartile ranges, and brackets are total range. CPB, Cardiopulmonary bypass; IL, interleukin.
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ative inflammatory response, overpowering any effect eli-
cited by RIPC. Finally, the number of patients included in
the study had no power to assess mortality.
CONCLUSIONS
Children undergoing RIPC on the day before cardiac sur-
gery had lower levels of NT-proBNP postoperatively, which
could indicate less myocardial dysfunction after CPB. Nev-
ertheless, this finding lacked clinical significance. Thus,
routine application of late RIPC alone for cardioprotection
in children with congenital heart disease undergoing car-
diac surgery with CPB currently cannot be recommended.
Future studies are needed to establish the ‘‘dose of ische-
mia’’ and the best moment to perform the procedure.
The authors thank Vanessa S. Silveira, PhD, who performed the
Western blot analyses, and Leticia F. Leal, MSc, for the contribu-
tion with real-time quantitative polymerase chain reaction
techniques.
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FIGURE E1. Flow diagram of the study.
FIGURE E2. Postoperative IkBa mRNA relative quantification in pa-
tients from RIPC (hashed boxes) and control (white boxes) groups. Central
lines are medians, boxes are interquartile ranges, and brackets are total
range. CPB, Cardiopulmonary bypass; IkBa, I kappa B alpha.
FIGURE E3. Postoperative IkBa mRNA relative quantification and total
NF-kB protein relative quantification of 3 randomly selected patients.
IkBa, I kappa B alpha; NF-kB, nuclear factor kappa B.
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